Trusted Resource for Clinical Trials, Protocols & Progress
Phase 3 trials are the final and most critical step before a drug can be submitted for approval. Analyzing successful case studies of Phase 3 programs that led to new drug approvals helps clinical researchers, regulatory teams, and students understand how strategy, design, and execution align to deliver high-impact results.
Click to read the full article.
Predicting a safe and pharmacologically relevant starting dose is one of the most critical decisions in early-phase clinical development. Pharmacometrics—the science of applying mathematical modeling and simulation to pharmacokinetic (PK) and pharmacodynamic (PD) data—plays a vital role in guiding dose selection, estimating exposure, and anticipating human variability before entering Phase 1. This tutorial explores how pharmacometric approaches such as allometric scaling, physiologically based pharmacokinetic (PBPK) modeling, and population PK (PopPK) support early trial design, reduce risk, and enhance regulatory confidence.
Click to read the full article.
In the post-approval phase of a drug’s lifecycle, detecting safety signals is paramount. Phase 4 trials, alongside spontaneous reporting systems and real-world data, form the foundation of modern pharmacovigilance. However, the volume, variety, and velocity of data generated in the real world call for more advanced tools beyond traditional manual reviews.
Click to read the full article.
Immunotherapy has transformed the treatment landscape for various cancers, autoimmune diseases, and chronic infections. As these therapies work by modulating the body’s immune system, Phase 2 trials for immunotherapies require distinct strategies that account for delayed responses, novel endpoints, and immune-related adverse events (irAEs). This tutorial outlines the key scientific, operational, and regulatory considerations in planning and executing Phase 2 trials for immunotherapy agents.
Click to read the full article.
As drug development becomes more focused on serious, life-threatening, and rare diseases, regulatory agencies have established expedited approval pathways to make promising therapies available faster. Two such pathways are the Accelerated Approval Program and the Fast Track Designation, primarily managed by the FDA.
Click to read the full article.
Phase 1 clinical trials are no longer limited to safety and pharmacokinetics. With the evolution of precision medicine, biomarkers have become essential tools in early development to characterize mechanism of action, monitor biological response, and support rational dose selection. Two major types of biomarkers—exploratory and predictive—are frequently integrated into Phase 1 protocols to bridge preclinical data with clinical outcomes. This article explains how to build a biomarker strategy in Phase 1 trials, the key differences between biomarker types, and how they align with regulatory expectations.
Click to read the full article.
Unlike prescription drugs, nutraceuticals and OTC products often reach consumers without the stringent pre-approval clinical testing required for pharmaceuticals. However, their widespread and long-term use in the general population demands close safety monitoring and evidence-based evaluation. This is where Phase 4 trials and post-marketing studies come into play—offering insights into adverse events, effectiveness, product misuse, and public health impact.
Click to read the full article.
Cell and gene therapies represent the frontier of modern medicine, offering potentially curative treatments for genetic disorders, cancers, and rare diseases. However, Phase 2 trials for these therapies introduce unique scientific, operational, manufacturing, and regulatory challenges. Unlike traditional small molecules or biologics, cell and gene therapies involve live or genetically modified components with complex delivery systems and long-term effects. This tutorial explores the specific hurdles and best practices associated with designing and managing Phase 2 clinical trials for cell and gene therapies (CGTs).
Click to read the full article.
Phase 3 trials aim to confirm the safety and efficacy of investigational drugs across a broad population. Yet, without adequate patient diversity and inclusion, the results may not fully reflect real-world effectiveness or safety. Diversity ensures that the approved therapy is safe, effective, and accessible to all populations it intends to serve—regardless of race, ethnicity, gender, age, geography, or socioeconomic status.
Click to read the full article.
The intersection of drugs and medical devices in a single product—known as a drug-device combination (DDC)—is transforming how therapies are delivered across areas like diabetes, asthma, oncology, and pain management. In early development, these products require integrated evaluation of device usability, drug delivery, and clinical performance. Planning a Phase 1 trial for a combination product involves navigating dual regulatory frameworks, conducting device-specific usability testing, and ensuring that drug pharmacokinetics are not compromised by delivery mechanics. This article offers a detailed guide to designing successful early-phase studies for combination products.
Click to read the full article.
